X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Sun Pharma Quarterly Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Sun Pharma Quarterly Results   (SUNP)

Here are the latest quarterly results of Sun Pharma. For more details, see the Sun Pharma financial fact sheet and Sun Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.

Excel Export | Annual Financial Info | Result Scoreboard

Sun Pharma Quarterly Results

No. of Mths
Qtr. Ending
3
Mar-17
*
3
Jun-17
*
3
Sep-17
*
3
Dec-17
*
3
Mar-18
*
3
Jun-18
*
3
Sep-18
*
3
Dec-18
*
8-Qtr Chart
Click to enlarge
Net Sales Rs m71,37062,08866,50366,53269,77172,24269,37677,402 
Other income Rs m2,2451,5202,5481,2923,0281,9983,5121,931 
Turnover Rs m73,61563,60869,05267,82472,79974,23972,88879,333 
Expenses Rs m55,89551,13152,74751,99952,93656,17554,06455,873 
Gross profit Rs m15,8851,45213,75614,53416,83516,0673,16821,529 
Depreciation Rs m3,3823,4663,5873,3934,5524,0164,2654,711 
Interest Rs m4501,0941,5749531,5541,3091,2951,448 
Profit before tax Rs m14,299-1,58911,14411,47913,75612,7391,11917,301 
Tax Rs m4431,6181,1147,487-1,7671,6392,1892,709 
Profit after tax Rs m13,856-3,20710,0303,99215,52311,101-1,07014,592 
Gross profit margin %22.32.320.721.824.122.24.627.8 
Effective tax rate %3.1-101.810.065.2-12.812.9195.615.7 
Net profit margin %19.4-5.215.16.022.215.4-1.518.9 
Diluted EPS Rs 5.8 -1.3 4.2 1.7 6.4 4.6 -0.4 6.1  
Diluted EPS (TTM) Rs 30.7 20.9 15.8 10.3 10.9 16.9 12.3 16.7  
 Subscriber Feature View View View            
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Read: Sun Pharma 3QFY19 Result Performance Review

More Pharmaceuticals Company Quarterly Results:   IPCA LABS  GLENMARK PHARMA  CADILA HEALTHCARE  NOVARTIS  GSK PHARMA  

Compare SUN PHARMA With:   IPCA LABS  GLENMARK PHARMA  CADILA HEALTHCARE  NOVARTIS  GSK PHARMA  

Compare SUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 404 Points Higher; Metal and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets continued their momentum during closing hours and ended the day on a strong note. Gains were largely seen in the metal sector and oil & gas sector.

Views on news

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

The RCom Bankruptcy: 5 Lessons for Smallcap Investors(Profit Hunter)

Feb 7, 2019

Managements of companies can create or ruin their fortunes. Why is management quality such an important factor in valuing businesses? Read on to find out...

The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)

Feb 13, 2019

The real estate sector is ready to make a comeback. This is the stock to consider buying.

How We Pick the Most Profitable Stocks from the Portfolios of Super Investors(The 5 Minute Wrapup)

Feb 8, 2019

This is the trick to following super investors and not losing money.

Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)

Feb 14, 2019

During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.

Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)

Feb 14, 2019

Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Feb 20, 2019 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUN PHARMA

SUN PHARMA - DR. DATSONS LABS COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS